Despite the fact that knocking down either RAC1 or RAC2 is adequate to reduce the transformed MLL-AF9 leukemia development; RAC2 but not RAC1, plays a dominant role in the initiation of acute myeloid leukemia in vivo [139]. The gene discussed is RAC2; the disease is leukemia.